BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma

被引：0
作者：
Brian W. Labadie
Ping Liu
Riyue Bao
Michael Crist
Ricardo Fernandes
Laura Ferreira
Scott Graupner
Andrew S. Poklepovic
Ignacio Duran
Saman Maleki Vareki
Arjun V. Balar
Jason J. Luke
机构：
[1] University of Chicago,Department of Internal Medicine
[2] University of Chicago,Department of Public Health Sciences
[3] University of Pittsburgh Medical Center,Hillman Cancer Center
[4] University of Pittsburgh,Division of Hematology/Oncology
[5] New York University School of Medicine and Langone Medical Center,Division of Hematology/Oncology
[6] Schulich School of Medicine & Dentistry,Division of Medical Oncology
[7] Western University and London Health Sciences Centre,Division of Medical Oncology
[8] University Hospital Marques de Valdecilla,Division of Hematology/Oncology
[9] Virginia Commonwealth University,undefined
来源：
Journal of Translational Medicine | / 17卷
关键词：
Renal cell carcinoma; Immune-checkpoint inhibition; Immunotherapy; Biomarkers; BMI;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 346 条
[1]  
Leibovich BC(2010)Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma J Urol 183 1309-1315
[2]  
Lohse CM(2019)Mutations of the VHL tumour suppressor gene in renal carcinoma Nat Genet 7 85-141
[3]  
Crispen PL(2005)Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma J Clin Oncol 23 133-1290
[4]  
Boorjian SA(2010)Immunotherapy for renal cell carcinoma Clin Dev Immunol 378 1277-1127
[5]  
Thompson RH(2009)Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 380 1116-567
[6]  
Blute ML(2018)Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma N Engl J Med 35 477-2501
[7]  
Gnarra JR(2019)Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma N Engl J Med 6 4-3085
[8]  
Tory K(2017)Impact of immune checkpoint protein expression in tumor cells and tumor infiltrating CD8+ T cells on clinical benefit from PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC) J Clin Oncol 515 563-2940
[9]  
Weng Y(2018)Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond J ImmunoTher Cancer 36 662-3692
[10]  
Schmidt L(2014)Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 377 2500-757
12345678910